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Abstract. The preclinical studies of 99mTc-1-Thio-D-glucose, a new tumor-seeking agent based on technetium-99m-
labeled glucose derivative, were conducted, and the feasibility of using this radiopharmaceutical for tumor visualization 
was studied. The preclinical studies were carried out strictly in accordance with the local legislation and were regulated 
by the generally accepted research standards. 99mTc-1-Thio-D-glucose was found to have optimal pharmacokinetic and 
physico-chemical properties for diagnostic imaging and was proved to belong to the low-toxic substances. The potential 
utility of 99mTc-1-thio-D-glucose for tumor imaging was studied in vitro and in vivo models. The present study 
demonstrated that 99mTc-1-Thio-D-glucose is a prospective radiopharmaceutical for cancer visualization.
INTRODUCTION
Early cancer detection is known to be a key element in increasing survival of cancer patients. Cancer is the 
second leading cause of death in Russia. The mortality rate has increased by 13.8% over the last 10 years.
Approximately 480,000 new cancer cases are diagnosed each year in Russia. Unfortunately, 60% of cancer patients 
are diagnosed in advanced stages. The effectiveness of medical care for cancer patients directly depends on the 
development and introduction of modern methods of nuclear medicine into medical practice.
Nuclear medicine techniques allow detection of functional abnormalities at early stages of disease, at the level of 
metabolic disturbances, thereby improving the likelihood of successful outcomes. However, the development of 
nuclear medicine imaging technologies in Russia is still far behind the world level. It is estimated that the demand 
for radiopharmaceuticals in Russia is satisfied by no more than 1–3%. In this regard, it seems relevant to develop 
new innovative radiopharmaceuticals for molecular imaging [1–3].
Glucose derivatives labeled with radioactive isotopes are promising radiopharmaceuticals for the early cancer 
detection [4]. This is due to the fact that malignant cells have an elevated level of glucose metabolism compared to 
normal cells. In addition, the number of specific glucose transporters has been increased in the cytoplasmic 
membranes of tumor cells, so the level of its entry into the cytoplasm is high. A variety of positron-emitting nuclides 
is currently utilized to detect tumors and metastases as well as to monitor treatment response. The most commonly 
used PET radiopharmaceutical is a derivative of glucose, namely 2-(18F) fluoro-2-deoxy-glucose (18F-FDG).
Despite the high diagnostic value of 18F-FDG-PET, the widespread use of this imaging modality in Russia is 
limited because of its high cost and lack of PET centers. The estimated cost of building a PET center is about 
1 billion rubles.
Currently, there are about 30 centers of positron emission tomography in Russia. However, along with a small 
number of PET centers, there are more than 200 SPECT centers (single-photon emission computed tomography). 
The most frequently used radionuclide for SPECT is technetium-99m. The main advantage of radiotracers based on 
technetium-99m-labeled glucose derivatives is the ability to image different tumor types using a gamma camera, 
thus significantly reducing the cost of the diagnostic procedure [5]. 
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FIGURE 1. Structural formula of 99mTc-1-Thio-D-glucose
The development of new radiopharmaceuticals based on technetium-99m- labeled glucose derivative will 
increase the number of cancer-related studies and allow cancer at early stages to be detected.
MATERIALS AND METHODS
The purpose of the study was the development and preclinical study of 99mTc-1-Thio-D-glucose, a new 
rdiopharmaceutical based on technetium-99m-labeled derivative of glucose, for cancer visualization. The structural 
formula of 99mTc-1-Thio-D-glucose is shown in Fig. 1.
The ready-made 99mTc-1-Thio-D-glucose contains a solution of 1-thio-D-glucose in the presence of tin (II) 
chloride dihydrate (SnCl2  2H2O). The radioactive label is technetium-99m from sodium pertechnetate solution 
(Na99mTcO4) from a sorption generator or sodium pertechnetate solution (Na99mTcO4) from an extraction 
generator. The composition of 99mTc-1-Thio-D-glucose is shown in Table 1.
Preclinical trials on the safety and efficacy of 99mTc-1-Thio-D-glucose were conducted in strict compliance with 
the guidelines for Preclinical Drug Development (A. Mironov). Toxicological studies of the new radiopharma-
ceutical included study of
– acute toxicity,
– cumulative effect,
– chronic toxicity,
– immune toxicity,
– mutagenicity,
– allergenicity,
– reproductive toxicity.
In addition, the pharmacokinetic parameters of 99mTc-1-Thio-D-glucose and its functional suitability were 
studied. The animals were kept in accordance with the rules adopted by the European Convention for the Protection 
of Animals (Strasbourg, 1986).
TABLE 1. The composition of 99mTc-1-Thio-D-glucose
Active substance 1 ml of the finished product contains
Technetium-99m as a complex with 1-thio-d-glucose 250–750 MBq
Excipients 1 ml of the finished product contains
99mTc-1-thio-D-glucose sodium salt hydrate No more than 0.625 mg
Tin dichloride 2-aqueous 0.044–0.052 mg
Ascorbic acid No more 0.125 mg
Sodium chloride 8.0–10.0 mg
Water for injections Up to 1 ml
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RESULTS
Study of Acute Toxicity of 99MTC-1-Thio-D-glucose
The study of acute toxicity suggested a single administration of 99mTc-1-Thio-D-glucose with subsequent 
monitoring of animals for 14 days. The aim of the study was to evaluate the tolerable, toxic and lethal doses of intra-
abdominal and intravenous injections of the radiopharmaceutical using the Litchfield and Wilcoxon methods, to 
determine the causes of death in animals and to study the effect of the radiopharmaceutical on functional and 
morphological parameters. The acute toxicity of 99mTc-1-Thio-D-glucose was studied in 80 rats (40 males and 
40 females) and 80 mice (40 males and 40 females). No changes in appearance, motor activity and behavior of 
animals were revealed during a 14-day follow-up period. The animals were followed-up for the first 8 hours after 
administration of the radiopharmaceutical, then daily. The effect of the radiopharmaceutical on the behavior, feed 
and water intake, appearance, motor activity, and animal response to external stimuli was studied. No anomalies 
were found. The animals were weighted before the experiment, then again at the end. All of the animals gained 
weight. The toxic effect of the radiopharmaceutical was not revealed. A postmortem examination was conducted 
after the completion of the 14-day follow-up period. During the entire follow-up period, there was no animal death. 
During autopsy, no differences were found between the animals of the experimental and control groups. No 
macroscopic and microscopic pathological changes in the internal organs of animals were revealed. Thus, acute 
toxicity studies showed that intravenous and intraperitoneal injections of 99mTc-1-Thio-D-glucose were well-
tolerated by rats and mice.
Study of the Cumulative Toxicity of 99MTC-1-Thio-D-glucose 
The cumulative toxicity of 99mTc-1-Thio-D-glucose was studied on 20 conventional outbred rats (10 males and 
10 females), 5 animals per group. The radiopharmaceutical was administered to animals by intraperitoneal injection 
of 12.5 ml/kg (1/2 LD50) daily for 28 days. The control group of animals received the same volume of saline. 
During the study, the animals were weighed once a week and monitored for one week. During this period, no animal 
deaths were observed. In the experimental group of rats (males and females) receiving the radiopharmaceutical, no 
statistically significant changes in the body weight index were observed in comparison with the control animals. 
There were also no changes in the body weight gain of experimental animals during the same follow-up period. 
Postmortem examination showed that the organs of the thoracic and abdominal cavities had anatomically correct 
position and normal macrostructure. No macroscopic pathological changes were found. Thus, the results of the study 
indicate that 99mTc-1-Thio-D-glucose has no cumulative toxicity.
Study of Chronic Toxicity of 99mTc-1-Thio-D-glucose
The chronic toxicity of 99mTc-1-Thio-D-glucose was studied on 80 rats weighing 250–350 g (males and females) 
and 12 rabbits. The radiopharmaceutical was intravenously administered to rats at doses of 0.2 ml/kg, 5 ml/kg, and 
10 ml/kg for 7 days. The animals were monitored for 30 days to assess their condition, weight and body temperature.
The assessment of peripheral blood, bone marrow, liver, kidneys, nervous system and heart was also carried out. In 
addition, the morphological examination of the internal organs and their weight was performed. None of the animals 
died during the follow-up period. Macroscopic and microscopic assessment of the internal organs showed no 
abnormalities in the functional activity of their internal organs and systems compared to the control group of animals.
Thus, 99mTc-1-Thio-D-glucose did not exert a toxic effect on the organs and systems of the animals. The study of 
immune toxicity, mutagenicity, allergenicity and reproductive toxicity revealed no significant abnormalities in the 
examined animals and their progeny after the administration of this radiopharmaceutical.
Study of the Pharmacokinetics of 99mTc-1-Thio-D-glucose
The main goal of the study of the pharmacokinetics of 99mTc-1-Thio-D-glucose was to analyze the distribution 
and excretion of this radiopharmaceutical in the bodies of the laboratory animals. The main organs and tissues of 
laboratory animals, in which the radiopharmaceutical was most intensively accumulated after its intravenous 
administration, were determined. 
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FIGURE 2. The curve of 99mTc-1-Thio-D-glucose concentration in the blood plasma. The balance between plasma 
concentration of 99mTc-1-Thio-D-glucose and extravascular concentration occurs 10 min after the intravenous 
injection of the radiopharmaceutical
The ways of elimination of 99mTc-1-Thio-D-glucose from the animals’ bodies were also identified. The study 
was conducted on 65 mature conventional outbred white male rats, males (weight: 250 ± 30 g, age: 10–12 weeks), 
and 9 Soviet chinchilla rabbits (weight: 2800–3100 g, age: 12–18 months).
In the first seconds after intravenous administration of 99mTc-1-Thio-D-glucose, it was quickly distributed in the 
blood plasma. The concentration of the radiopharmaceutical in the blood plasma began to decrease 1 minute after its 
injection. The radiopharmaceutical was actively subjected to glomerular filtration and was detected in the renal 
parenchyma and urine 1 min after the injection. The radiopharmaceutical did not penetrate through the intact blood-
brain barrier, as evidenced by its insignificant concentration in the brain of animals, mainly due to the presence of 
blood in the membranes of the brain. The half-life of 99mTc-1-Thio-D-glucose from the blood plasma (T1/2) was 
10 min (Fig. 2). It should be noted that the radiopharmaceutical was not detected in the blood plasma of laboratory 
animals 24 hours after the injection, that is, the radiopharmaceutical was completely eliminated from the blood 
plasma 24 hours after its injection.
The radiopharmaceutical was excreted by glomerular filtration. The mean concentrations of 99mTc-1-Thio-D-
glucose in the main organs and tissues of laboratory animals in 30 s, 1, 3, 10 and 30 min, 1, 3, 10 and 24 hours after 
intravenous administration are shown in Table 2.
TABLE 2. The average concentration of 99mTc-1-Thio-D-glucose in organs and tissues of rats 
after single injection of this radiopharmaceutical (%/g)
Organs 30 s 1 min 3 min 10 min 30 min 1 h 3 h 10 h 24 h
Blood
13.856 ±
0.236
12.34 ±
0.517
9.378 ±
0.294
6.514 ±
0.367
1.876 ±
0.039
0.240 ±
0.014
0.0032 ±
0.004 0.000 0.000
Brain 0.0000 0.000
0.010 ±
0.014
0.012 ±
0.011
0.008 ±
0.011 0.000 0.0000 0.000 0.000
Heart
0.0800 ±
0.036
0.088 ±
0.045
0.098 ±
0.034
0.084 ±
0.035
0.116 ±
0.024 0.040 0.0000 0.000 0.000
Lungs
0.0260 ±
0.013
0.042 ±
0.022
0.036 ±
0.023
0.062 ±
0.018
0.038 ±
0.016
0.028 ±
0.011
0.0000 0.000 0.000
Liver
0.0016 ±
0.002
0.007 ±
0.003
0.092 ±
0.008
0.066 ±
0.005
0.028 ±
0.004
0.007 ±
0.007
0.0000 0.000 0.000
Spleen
0.0120 ±
0.016
0.018 ±
0.016
0.196 ±
0.047
0.135 ±
0.034
0.066 ±
0.013
0.000 0.0000 0.000 0.000
Small 
intestine
0.0000 0.000 0.000 0.000 0.000 0.000 0.0000 0.000 0.000
Colon 0.0000 0.000 0.000 0.000 0.000 0.000 0.0000 0.000 0.000
Kidneys
0.388 ±
0.018
1.894 ±
0.069
4.540 ±
0.378
4.340 ±
0.247
3.364 ±
0.021
0.408 ±
0.029
0.0040 ±
0.009
0.000 0.000
Urine 0.0000
3.082 ±
0.193
6.146 ±
0.322
18.338 ±
1.019
28.500 ±
0.757
39.004 ±
1.595
30.990 ±
3.761
21.996 ±
0.304
2.596 ±
0.036
Muscle 0.0000 0.000
0.104 ±
0.015
0.096 ±
0.017
0.064 ±
0.017
0.008 ±
0.010
0.0000 0.000 0.000
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FIGURE 3. The curve of the concentration of 99mTc-1-Thio-D-glucose 
in the blood plasma RIUDWVDWGLIIHUHQWGRVHOHYHOVDQGɆ%T
The data obtained confirmed the linearity of pharmacokinetics of 99mTc-1-Thio-D-glucose. It was found that the 
concentration of the radiopharmaceutical in the blood plasma of laboratory animals proportionally increased with 
increasing doses. The pharmacokinetic curve of 99mTc-1-Thio-D-glucose is shown in Fig. 3.
The distribution and accumulation of 99mTc-1-Thio-D-glucose, which was injected for 5 days, corresponded to 
the distribution of the radiopharmaceutical after its single injection, thus indicating that 99mTc-1-Thio-D-glucose did 
not have cumulative effect and did not accumulate persistently in the main organs and tissues of the animals.
Study of Potential Utility of 99mTc-1-Thio-D-glucose
The potential utility of 99mTc-1-thio-D-glucose was studied in vitro and in vivo models. In vitro studies, cell 
cultures from normal (Chinese hamster ovary (CHO) cells) and cancer tissues (MCF 7–human breast 
adenocarcinoma cell line) were used. 50 MBq of 99mTc-1-thio-D-glucose was added to vials with 1,000,000 cells/ml, 
5 vials for each cell culture. The vials with cells were then incubated for 40 minutes at room temperature with 
periodic gentle shaking to avoid cell adhesion. After completion of incubation, the vials were centrifuged at 300 rpm 
for 5 min. After sedimentation, the supernatant was removed and the radioactivity measurement of the sediment and 
supernatant was made. Thereafter, cells were washed three times by adding 1 ml of buffer to each vial. PBS + 1% 
BCA were used as a buffer.
After the final cell washing, the 99mTc-labeled 1-thio-D-glucose uptake in normal and cancer tissue cells was 
measured using E.CAM180 gamma camera (Siemens, Germany). The study results demonstrated that the 99mTc-
labeled 1-thio-D-glucos uptake in cancer cells (MCF 7) was 2 times higher than that in normal tissue cells (CHO). 
The mean radioactivity levels in cancer and normal tissue cells after the final washing were 7.21 ± 0.4 and 13.7 ± 0.6, 
respectively. Planar scintigraphic images of plates with culture vials showed more intense radiotracer uptake in 
cancer tissue cells than in normal cells (Fig. 4).
FIGURE 4. Scintigraphic imaging of the 99mTc-1-Thio-D-
glucose uptake: 1—cancer tissue cells, 2—normal tissue cells
FIGURE 5. Scintigraphic image of a tumor bearing mouse at 
15 min after intravenous injection of 99mTc-labeled 1-thio-D-
glucose. High 99mTc-1-thio-D-glucose uptake in the tumor 
of the right femur (1)
020083-5
In vivo studies, the potential utility of 99mTc-labeled 1-thio-D-glucose was studied using the intramuscularly 
implanted solid Lewis lung carcinoma model in C57B1/6J mice. A total of 50 male and female mice, weighing 
28 ± 5g and 8–10 weeks of age, were used. The median tumor size in mice was 1.67 ± 0.12 cm3. The mice were 
anesthetized by inhalation of ethyl ether. The radiopharmaceutical at a dose of 20 MBq was intravenously injected 
to C57BL/6J mice bearing Lewis lung carcinoma and to the control group mice. Whole-body gamma scintigraphy 
using the e.cam® Siemens dual-head 180° gamma camera was performed 40 min after intravenous injection of the 
radiopharmaceutical. The mice were placed with their ventral surface to the gamma camera detector so that the 
imaging field of view could encompass the whole body of the animal. Each image was acquired for 5 min. About 
500,000 counts were recorded in each image with matrix size of 256u256 pixels. The high-resolution, low-energy 
collimators for 140 keV energy were used. Statistical analysis was performed using E.Soft software (SIEMENS, 
Germany).
Scintigraphic images demonstrated extremely high 99mTc-1-Thio-D-glucose uptake in tumor tissue of all mice 
bearing Lewis lung carcinoma (Fig. 5). In the control group animals, the radiopharmaceutical accumulated more 
intensively in the kidneys and bladder. The tumor-to-background ratio was 4.15 ± 0.35. As a background, a 
contralateral region of a healthy limb was used.
CONCLUSION
In the preclinical studies, 99mTc-1-thio-D-glucose demonstrated no toxic effect on the main organs and systems 
of laboratory animals. Based on the results of toxicological studies, 99mTc-1-Thio-D-glucose was classified as a class 
of low-toxic substances.
It should be noted that 99mTc-1-Thio-D-glucose has optimal physical/chemical and pharmacokinetic parameters 
for the diagnostic imaging. This radiopharmaceutical does not penetrate through the intact blood-brain barrier and 
does not accumulate persistently in the main organs and tissues. 99mTc-labeled 1-thio-D-glucose is excreted from the 
kidneys by glomerular filtration.
In vitro study of potential utility of 99mTc-1-Thio-D-glucose for tumor visualization showed more intense 
radiotracer uptake in cancer tissue cells than in normal cells. In vivo studies indicated that the 99mTc-1-Thio-D-
glucose uptake in tumor tissues was significantly higher than that in intact tissues.
Thus, 99mTc-1-Thio-D-glucose, a new tumor-seeking agent based on technetium-99m-labeled glucose derivative, 
is a promising radiopharmaceutical for cancer visualization by SPECT. It is characterized by low cost of production 
and ease of use in the standard nuclear medicine laboratory.
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